Needham initiated coverage of Lyell Immunopharma (LYEL) with a Buy rating and $44 price target The firm says the company’s ronde-cel is in the “pole position” for second-line diffuse large B-cell lymphoma. Lyell’s “bold head-to-head development strategy” has the potential to make ronde-cel the CAR-T of choice in second-line DLBCL, the analyst tells investors in a research note. Needham views the company as an “under-the-radar name with undervalued assets.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYEL:
- Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential
- Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital
- Lyell Immunopharma appoints Smital Shah as CFBO
- Lyell Immunopharma initiated with an Outperform at Citizens
- LYEL Earnings this Week: How Will it Perform?